| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e03573f864c1e834ee1afabce10f4cfd |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
| filingDate |
2018-01-16^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c05eacd4534a8ff5a20166596733f272
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76d4f648af59961adff60e8f0a0e5a74 |
| publicationDate |
2018-07-26^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018134189-A1 |
| titleOfInvention |
Co-crystal of an antitumoral compound |
| abstract |
he present invention relates to a co-crystal of Dasatinib with triethyl citrate, processes for its preparation, pharmaceutical compositions thereof and its use in the treatment of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11052088-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11160805-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11007195-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10940149-B1 |
| priorityDate |
2017-01-20^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |